Literature DB >> 16061832

The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index.

Ginevra Corneli1, Carolina Di Somma, Roberto Baldelli, Silvia Rovere, Valentina Gasco, Chiara Giulia Croce, Silvia Grottoli, Mauro Maccario, Annamaria Colao, Gaetano Lombardi, Ezio Ghigo, Franco Camanni, Gianluca Aimaretti.   

Abstract

OBJECTIVE: The diagnosis of growth hormone (GH) deficiency (GHD) in adults is based on a reduced peak GH response to provocative tests, such as the insulin tolerance test (ITT) and the GH-releasing hormone-arginine (GHRH-ARG) test. However, the cut-off limits of peak GH response in lean subjects are not reliable in obese patients; this is noteworthy since adult GHD is often associated with obesity. Aim of this study was to evaluate the diagnostic cut-off limits of peak GH response to the GHRH-ARG test in overweight and obese as well as in lean population. DESIGN AND METHODS: The GH responses to the GHRH-ARG test were studied in 322 patients with organic hypothalamic-pituitary disease and in 318 control subjects. Patients were subdivided into two groups on the basis of the number of pituitary hormone deficits, except for GH deficiency: (a) patients with total pituitary hormone deficit (TPHD) and (b) patients without or with no more than two pituitary hormone deficits (PHD). Both patients and control subjects were divided into three subgroups according to body mass index (BMI): lean (BMI <25 kg/m(2)), overweight (BMI > or = 25 and <30 kg/m(2)) and obese (BMI > or =30 kg/m(2)). TPHD patients were assumed to be GH deficient, whereas PHD patients may include subjects with either normal or impaired GH secretion. The statistical analysis was carried out by the Receiver-Operating Characteristic curve analysis (Medcalc 7.2). The diagnostic cut-off points were calculated for lean, overweight and obese subjects to provide optimal separation of GH-deficient patients and control subjects according to two criteria: (1) a balance between high sensitivity and high specificity; (2) to provide the highest pair of sensitivity/specificity values for GH deficiency.
RESULTS: In the lean population the best pair of values, with highest sensitivity as 98.7% and highest specificity as 83.7%, was found using a peak GH cut-off point of 11.5 mug/l. In the overweight population the best pair of values, 96.7 and 75.5%, respectively, was found using a peak GH cut-off point of 8.0 mug/l. In the obese population the best pair of values, 93.5 and 78.3%, respectively, was found using a peak GH cut-off point of 4.2 mug/l. Applying the above mentioned cut-off points, among PHD patients we found that 80 subjects (72%) were GHD whereas 31 (28%) had normal GH secretion.
CONCLUSIONS: In conclusion the GHRH-ARG test is a reliable tool for the diagnosis of adult GH deficiency in lean, overweight and obese patients, provided that specific BMI-related cut-off limits are assumed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061832     DOI: 10.1530/eje.1.01967

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  87 in total

Review 1.  Growth hormone treatment in adults with growth hormone deficiency: the transition.

Authors:  M E Molitch
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

2.  Diagnosis: a reappraisal of the diagnosis of growth hormone deficiency.

Authors:  Gudmundur Johannsson
Journal:  Nat Rev Endocrinol       Date:  2010-04       Impact factor: 43.330

3.  Serum insulin-like growth factor-1 concentrations are reduced in severely obese women and raise after weight loss induced by laparoscopic adjustable gastric banding.

Authors:  Giulia Galli; Aldo Pinchera; Paolo Piaggi; Paola Fierabracci; Monica Giannetti; Giorgia Querci; Giovanni Scartabelli; Luca Manetti; Giovanni Ceccarini; Silvia Martinelli; Claudio Di Salvo; Marco Anselmino; Fausto Bogazzi; Alberto Landi; Paolo Vitti; Margherita Maffei; Ferruccio Santini
Journal:  Obes Surg       Date:  2012-08       Impact factor: 4.129

Review 4.  The rational use of pituitary stimulation tests.

Authors:  Stephan Petersenn; Hans-Jürgen Quabbe; Christof Schöfl; Günter K Stalla; Klaus von Werder; Michael Buchfelder
Journal:  Dtsch Arztebl Int       Date:  2010-06-25       Impact factor: 5.594

Review 5.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

Review 6.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

7.  Impairment of GH secretion in amyotrophic lateral sclerosis is not affected by riluzole treatment.

Authors:  L L Morselli; P Bongioanni; M Genovesi; R Licitra; B Rossi; L Murri; F Bogazzi; E Cecconi; E Martino; M Gasperi
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study.

Authors:  Daniel F Kelly; Charlene Chaloner; Diana Evans; Amy Mathews; Pejman Cohan; Christina Wang; Ronald Swerdloff; Myung-Shin Sim; Jihey Lee; Mathew J Wright; Claudia Kernan; Garni Barkhoudarian; Kevin C J Yuen; Kevin Guskiewicz
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

9.  The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.

Authors:  Alessandro Ciresi; Stefano Radellini; Valentina Guarnotta; Carla Giordano
Journal:  Endocrine       Date:  2016-08-13       Impact factor: 3.633

10.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.